Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Notice of Extraordinary General Meeting/Proxy Form

Saturday, March 15, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates have been shared regarding four of its clinical programs.
Price reaction · baseline $5.8 (2025-03-14 close) · 2 other RADX headline(s) in the window, move may be shared
day 0 close · peak
+6.9%
day 1
-2.8%
day 3
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates have been reported across four programs.

Full Press Release Details

• Announcements
• March 15, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• December 19, 2024
• Announcements
• November 22, 2022
• Announcements
• August 28, 2024
• Announcements
• October 18, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) study about?

The BetaBart (RV-01) study is a Phase 1/2a clinical trial targeting B7H3.

Who approved the BetaBart clinical study?

The US FDA approved the IND for the BetaBart clinical study.

When was the first patient dosed in the study?

The first patient was dosed in the Phase 1/2a study recently.

What updates has Radiopharm provided?

Radiopharm has provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a B7H3 FDA IND approval
Last updated: Mar 15, 2025